Globally, the incidence of sarcoma in young adults is approximately 2/100,000 persons with a greater incidence in males over females by a 2:1 ratio. Previous radiation and chemotherapy exposure before the age of 20, as well as exposure to certain chemical agents, has been linked to an increased risk in the development of sarcoma in the young adult population. Young adult sarcoma patients seem to do worse then their pediatric counterparts for a variety of reasons, one being the differences in the biology of their cancers. These differences in biology need to be accounted for when establishing treatment plans in this age group in determining pediatric- versus adult-based protocols.
Source: Soliman H, Ferrari A, Thomas D. Sarcoma in the Young Adult Population: An International View. Semin Oncol. 2009; 36:227-236.
Sodium butyrate (SB) augments the effects of 1,25 dihydroxyvitamin D3 (1,25(OH)2D3) on neoplastic and osteoblastic phenotype in clonal rat osteosarcoma cells.
Biochem Biophys Res Commun. 1984 Jun 29;121(3):796-801
Authors: Yoneda T, Aya S, Sakuda M
1,25 Dihydroxyvitamin D3 suppressed colony formation in soft agar and...
Recruitment and follow-up of adolescent and young adult cancer survivors: the AYA HOPE Study.
J Cancer Surviv. 2011 Sep;5(3):305-14
Authors: Harlan LC, Lynch CF, Keegan TH, Hamilton AS, Wu XC, Kato I, West MM, Cress...
from patients, caregivers and medical professionals dealing with this disease and many other diseases